52 results
PRE 14C
BTAX
Biostax Corp.
16 Dec 22
Preliminary information
4:31pm
:
(a) The term “proceeding” shall be broadly construed and shall include, without limitation, the investigation, preparation, prosecution, defense, settlement
8-K
EX-10.1
BTAX
Biostax Corp.
22 Jul 22
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer
3:44pm
in an agency investigation; provided, however, that the Executive hereby waives his right to recover any money in connection with such charge … or investigation. Moreover, nothing in this Separation Agreement limits or waives, or is intended to limit or waive, the Executive’s right pursuant to the Older
8-K
EX-10.1
srntt yg3
11 Jun 18
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.2
n9z089lzv4g26 hfo
11 Jun 18
Entry into a Material Definitive Agreement
12:00am
S-1
36vtih3y
14 Oct 16
IPO registration
12:00am